Better Buy: CRISPR vs. Fulgent Genetics

Jim Halley, The Motley Fool
·5-min read
Better Buy: CRISPR vs. Fulgent Genetics

CRISPR Therapeutics (NASDAQ: CRSP) and Fulgent Genetics (NASDAQ: FLGT) operate at different ends of the scientific gene pool. CRISPR, named for the Nobel Prize-winning CRISPR gene-editing technique, is a clinical-stage biotech company that is looking for gene-editing therapies to treat blood disorders, cancer, diabetes, and other diseases. Fulgent Genetics, meanwhile, is a genetics testing provider that uses next-generation sequencing (NGS) to study genetic variations connected with diseases or other biological phenomena.